Esperion Therapeutics (ESPR) Cash from Investing Activities: 2018-2024
Historic Cash from Investing Activities for Esperion Therapeutics (ESPR) over the last 5 years, with Sep 2024 value amounting to -$167,000.
- Esperion Therapeutics' Cash from Investing Activities was N/A to -$167,000 in Q3 2024 from the same period last year, while for Sep 2024 it was $17.2 million, marking a year-over-year change of. This contributed to the annual value of -$317,000 for FY2024, which is 100.75% down from last year.
- Esperion Therapeutics' Cash from Investing Activities amounted to -$167,000 in Q3 2024, which was down 116.88% from -$77,000 recorded in Q2 2024.
- In the past 5 years, Esperion Therapeutics' Cash from Investing Activities registered a high of $33.0 million during Q3 2022, and its lowest value of -$50.5 million during Q4 2021.
- In the last 3 years, Esperion Therapeutics' Cash from Investing Activities had a median value of -$73,000 in 2024 and averaged $5.6 million.
- Its Cash from Investing Activities has fluctuated over the past 5 years, first slumped by 341.98% in 2020, then soared by 250.00% in 2023.
- Esperion Therapeutics' Cash from Investing Activities (Quarterly) stood at -$12.7 million in 2020, then slumped by 298.26% to -$50.5 million in 2021, then soared by 76.64% to -$11.8 million in 2022, then soared by 250.00% to $17.5 million in 2023, then slumped by 100.44% to -$167,000 in 2024.
- Its last three reported values are -$167,000 in Q3 2024, -$77,000 for Q2 2024, and -$73,000 during Q1 2024.